The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The study will assess the real life effectiveness of zoledronic acid in the management of patients with osteoporosis over 4 years of treatment. Zoledronic acid will be compared to oral bisphosphonates (OBP) with respect to the change in Bone Mineral Density (BMD) and incidence of fractures.
Condition or disease
Drug: zoledronic acidDrug: Any oral bisphosphonates marketed in Canada
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
45 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Ambulatory Female patients, at least 45 years of age, diagnosed with osteoporosis and taking either Zelodronic acid or any other oral bisphosphonates (OBP) as per the current Canadian monograph
Patient is an ambulatory female 45 years of age or older
Postmenopausal women with diagnosis of osteoporosis
Prescription of zoledronic acid or any OBP as per the current Canadian monograph
Must provide informed consent
Any prior use of iv bisphosphonates within the last 2 years
Known secondary osteoporosis of any aetiology (hypogonadism in premenopausal women or premature menopause, malabsorption, chronic liver disease, inflammatory bowel disease)
Metabolic bone diseases such as primary or secondary hyperparathyroidism, hypoparathyroidism, Paget's disease of bone, Fibrous dysplasia..
Non-corrected hypocalcaemia at the time of zoledronic acid infusion
Creatinine clearance < or = 30 ml/min
Unwillingness or inability to comply with the study requirements
Concurrent participation in a clinical trial of an investigational drug, or within the last 30 days
Other protocol-defined inclusion/exclusion criteria may apply.